Contrafect Corp (CFRX)

[trickledownfacists]

Zacks $30 PT
https://s1.q4cdn.com/460208960/files/News/2020/Zacks_SCR_Research_02182020_CFRX_Bautz.pdf

[SweatpantKing]

Nice, this is all over the place but it will keep rising.

[Armed n Hammered]

I am glad I got into this a month ago !!!!!!!

[trickledownfacists]

Congrats longs

[SweatpantKing]

Thanks, I just read that seekingalpha article as well. Looking forward to the future.

[trickledownfacists]

They have around $25M in the bank and a possible grant coming.

[SweatpantKing]

Any idea on the dilution/funding needed. The technology works (on everything but left-endocarditis). I need more shares!

[trickledownfacists]

Total Float is 12.5M

Federated owns 3.5M
Pfizer owns 1.1M
Fosun owns 1.1M
Baker owns 800,000
Feinberg owns 700,000
Cormorant owns 700,000
Other funds own 1.4M

Totaling 9.3M shares held in Funds....

LEAVING 3.2 MILLION SHARES IN THE FLOAT

[trickledownfacists]

https://seekingalpha.com/article/4322942-contrafect-game-changing-treatment-for-superbug-mrsa?utm_source=dashboard.stck.pro&utm_medium=referral

[trickledownfacists]

Great volume.

[Marvy]

Big money buying up shares.

[trickledownfacists]

Holding very strong after RS

Breakthrough decision from FDA soon

[iancnyc]

ahhh just like the stinky pinky’s do
disgusting

[trickledownfacists]

RS approved

They will meet listing standards bring the float to 12M and funds will be able to buy

[iancnyc]

Horrible pump and dump
death spiral to sub penny here we come

[iancnyc]

scam stinky pinky
belongs on the pink sheets with all the other pump and dump scams

[Fanthos]

Check out cocp, runner for sure.

[iancnyc]

Maybe they’re pushing it down just a bouncer tomorrow loading up

[Fanthos]

It met compliance and nobody ran it. Lost a few cents here. Oh well.

[iancnyc]

pump and dump penny crap
should be on the pinks

[Fanthos]

Bummer. No conpliance run. Bust.

[trickledownfacists]

ContraFect to Present at 2020 ASM Biothreats

Source: GlobeNewswire Inc.

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research has been invited to discuss the potential role of DLAs to combat high consequence biodefense and biologic threats at 2020 American Society of Microbiology (ASM) Biothreats, being held January 28 – 30, 2020 at the Hyatt Regency Crystal City in Arlington, Virginia.
Dr. Cassino’s talk, “Direct Lytic Agents: Novel Pipeline For Biothreat Defense”, will include an overview of the Company’s DLA pipeline, including agents with potential utility against biowarfare threats, such as anthrax and other weaponizable pathogens. Dr. Cassino will also discuss the potential role of the Company’s lead product candidate exebacase, currently being studied in a pivotal Phase 3 trial, in addressing the downstream threat of hospital-acquired MRSA bacteremia for a potential bio-threat exposure with mass casualty events.

Presentation Details:

Presentation Title: Direct Lytic Agents: Novel Pipeline for Biothreat Defense
Session Title: New Developments in Antimicrobials
Room: Potomac
Time and Date: Wednesday, January 29, 2020, 1:30 p.m. – 1:55 p.m. ET

A copy of the presentation will be available on the Investors & Media section of the Company’s website at www.contrafect.com.

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a new class of DLAs, which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as methicillin-resistant Staph aureus (MRSA) and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S.

Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.

Forward-Looking Statements:

This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding ContraFect’s ability to discover and develop DLAs as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, statements made regarding the conference and the presentation, statements made regarding DLAs, including exebacase, and their role in bio-threats and biodefense, ContraFect’s ability to address life threatening infections using its DLA platform, whether lysins are a new class of DLAs which are recombinantly produced, antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics, whether amurins exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens and whether the properties of ContraFect’s lysins and amurins will make them suitable for targeting antibiotic-resistant organisms, such as Staph aureus and P. aeruginosa. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including those detailed under the caption “Risk Factors” in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contacts:

Michael Messinger
ContraFect Corporation
Tel: [phone]
Email: [e-mail]

Lauren Stival
Stern Investor Relations
Tel: [phone]
Email: [e-mail]


Primary Logo

[trickledownfacists]

Break that $1.12 wall

[Master MooLah]

True. Lol. Well I’m looking for a nice bounce.

[iancnyc]

who knows i was prob high

[Master MooLah]

I don’t get what you mean? It hasn’t broken $1 yet. I’m just looking at the chart but doesn’t look like a dump.

[iancnyc]

guess this is just another pump and dump
seems to be following that good old pattern
can’t hold gains for shit
on its way back to penny’s

[trickledownfacists]

Article:

https://seekingalpha.com/article/4316976-contrafect-corporation-is-differentiated-infectious-disease-pick-for-2020

[trickledownfacists]

Presentation:

https://event.webcasts.com/viewer/event.jsp?ei=1279594&tp_key=1bf47c242d

[Viewmont]

Very solid after market, last trade was $1.29.

[Viewmont]

Strong buy signal at Barchart.
88% BUY
Overall Average Signal calculated from all 13 indicators. Signal Strength is a long-term measurement of the historical strength of the Signal, while Signal Direction is a short-term (3-Day) measurement of the movement of the Signal.

[Viewmont]

Nice! it looks like you're doing good! Congrats!

It closed high and after hours is still going higher.

[trickledownfacists]

CEO says $700M to $1.5BILLION IN SALES.

Got everything they wanted from FDA.

Turned down an acquisition.

HUGE!!!

[Marvy]

They turned down a M&A.

Pfizer is an investor

Pfizer giving assistance

[ClayTrader]

* * $CFRX Video Chart 01-13-2020 * *

Link to Video - click here to watch the technical chart video

[trickledownfacists]

Vote no

[CyrusDaVirus]

Interesting!!! Ill put it on my radar

[trickledownfacists]

$10

[CyrusDaVirus]

Where does that put this as far as valuation?

[trickledownfacists]

Worth $1-$2B with approval

[iancnyc]

Looks like we
are staying way above 1.03
how high will this go???

[PepsiMan]

This is great news! I have been following this since under a dollar.



$CFRX


PEPSI

[Viewmont]

https://www.contrafect.com/pipeline/overview

Product Candidates
The next generation of anti-infectives.
We intend to develop and commercialize novel, first-in-class biologic therapies, known as direct lytic agents (DLAs), to treat life-threatening infections, including those caused by drug-resistant pathogens. The increasing prevalence of antibiotic resistance among bacterial pathogens has been widely recognized as an urgent public health threat by the CDC, the WHO and the Infectious Disease Society of America.
Our lead lysin, exebacase (CF-301) is an investigational product candidate that targets Staph aureus, including MRSA strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis. We have announced positive results from this first-in-patient Phase 2 superiority study of exebacase, which showed clinically meaningful improvement in clinical responder rates among patients treated with exebacase in addition to standard-of-care (“SOC”) antibiotics compared to SOC antibiotics alone. We have developed a novel, engineered variant of exebacase, CF-296, with potential as a targeted therapy for deep-seated, invasive biofilm-associated Staph aureus infections such as prosthetic joint infections. Our research efforts are focused on a broad-based Gram-negative discovery program which aims to identify, optimize and develop DLAs that target deadly Gram-negative pathogens. We have discovered and engineered lysins with potent activity against drug-resistant Pseudomonas aeruginosa (“P. aeruginosa”) bacteria, a major cause of morbidity and mortality in patients with hospital acquired pneumonia and a major medical challenge for patients with cystic fibrosis. We have also discovered a novel class of phage-derived DLAs, known as amurin peptides, which have displayed potent activity against a wide range of Gram-negative pathogens in preclinical studies, including deadly, drug-resistant P. aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii and Enterobacter cloacae bacteria species.

[Viewmont]

YONKERS, N.Y., Jan. 10, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the first patient has been dosed in the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis.

“We are pleased by the rapid enrollment and dosing of the first patient in the Phase 3 pivotal study of our lead lysin candidate, exebacase, which we believe has the potential to improve clinical outcomes for patients suffering and dying from Staph aureus bacteremia, particularly those infected with difficult to treat methicillin-resistant Staph aureus (MRSA). We are confident in the protocol for the Phase 3 study which aims to be the first pivotal study to demonstrate superiority over standard of care antibiotics alone for the treatment of MRSA bacteremia,” said Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research and Development of ContraFect. “We believe exebacase and our pipeline of DLA candidates have the potential to be game changers in the fight against drug-resistant pathogens.”

The Phase 3 DISRUPT study of exebacase is a randomized, double-blind, placebo-controlled clinical study conducted in the U.S. to assess the efficacy and safety of exebacase in approximately 350 patients with complicated Staph aureus bacteremia, including right-sided endocarditis. Patients entering the Phase 3 study will be randomized 2:1 to either exebacase or placebo, with all patients receiving standard-of-care antibiotics. The primary efficacy endpoint will be clinical response at Day 14 in patients with MRSA bacteremia, including right-sided endocarditis. Secondary endpoints will include clinical response at Day 14 in the All Staph aureus patients (MRSA and methicillin-sensitive Staph aureus (MSSA)), 30-day all-cause mortality in MRSA patients, and clinical response at later timepoints. The company plans to conduct an interim futility analysis following the enrollment of approximately 60% of the study population.

[Viewmont]

ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

[Viewmont]

ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

[Viewmont]

YONKERS, N.Y., Jan. 13, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has extended early access to exebacase to individual named patients with chronic post-operative prosthetic joint infections (PJIs) under Temporary Authorizations for Use (ATUs) from the French National Agency for Medicines and Health Products Safety (ANSM) in collaboration with Dr. Tristan Ferry at the Hôpital de la Croix Rousse in Lyon, France.

Four patients with longstanding, treatment-refractory PJIs have been treated with direct administration (i.e. intra-articular) of exebacase to the affected joint under ATUs. Based on promising clinical signals in these exebacase-treated patients, temporary authorization for use of exebacase has now been extended to patients with Staphylococcal PJI occurring early in the postoperative period, to potentially avoid significant loss of function.

“Staphylococcal PJIs pose significant treatment challenges due to biofilm formation which renders conventional antibiotics ineffective and necessitates surgical removal and replacement of the joint. Exebacase has the demonstrated potent ability to eradicate Staphylococcal biofilms in vitro and in animal models, and thus may have potential as a therapeutic agent administered directly to the joint to clear the infection and possibly reduce the need for surgical intervention,” said Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research and Development of ContraFect. “This would be a significant benefit to patients world-wide, as there are currently no approved medical treatments for PJIs, and surgical reimplantation of a new prosthetic joint can be associated with substantial disability and loss of function.”

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing differentiated biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a new class of DLAs, which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including Pseudomonas aeruginosa (P. aeruginosa), Acinetobacter baumannii, and Enterobacter species. We believe that the properties of our lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as methicillin-resistant Staph aureus (MRSA) and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. We have completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with our lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S.

Follow ContraFect on Twitter @ContraFectCorp and LinkedIn.

[Viewmont]

ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections

[iancnyc]

oh yes going to the north pole
$10 a share in 3
months time

[ClayTrader]

* * $CFRX Video Chart 01-10-2020 * *

Link to Video - click here to watch the technical chart video